ArticleAmerican journal of translational research2022
Clinical value of prophylactic transcatheter arterial chemoembolization treatment in patients with hepatocellular carcinoma.
Article in American journal of translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
- Prophylactic transarterial chemoembolization after R0 resection is beneficial to improve the prognosis in hepatocellular carcinoma patients with microvascular invasion.Discover oncology · 2025Article
- Combined Effects of Anti-PD-L1 and Nanosonodynamic Therapy on HCC Immune Activation in Mice: An Investigation.International journal of nanomedicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the feasibility of surgical resection combined with prophylactic transcatheter arterial chemoembolization (TACE) in reducing the recurrence and improving the survival rate of patients with hepatocellular carcinoma (HCC).
methodsIn this retrospective study, 76 patients with HCC treated in our hospital from February 2016 to December 2018 were enrolled. Among them, 31 patients who received radical surgery alone were enrolled as the control group, and 45 patients who received prophylactic TACE within 6 months after radical surgery were enrolled as the study group. All cases were followed up for 36 months. The recurrence rate, survival rate, and median survival time of patients at 1, 2, and 3 years after surgery were compared between the two groups. Patients in the study group were divided into subgroup A (interventional therapy within 1 month), subgroup B (interventional therapy within 1-2 months), subgroup C (interventional therapy within 2-3 months), and subgroup D (interventional therapy within 3-6 months). The recurrence rate within 1 year was compared among the four subgroups. Finally, the clinical indicators affecting the recurrence of HCC were analyzed.
resultsThe recurrence rate at 1, 2 and 3 years after surgery in the study group was lower than that in the control group (all P<0.05). The survival rate at 1, 2 and 3 years after surgery in the study group was higher than that in the control group (all P<0.05). The median survival time of patients in the study group was slightly higher than that in the control group, with no significant difference (P>0.05). The 1-year recurrence rate of patients in subgroups A and B was significantly lower than that in subgroups C and D (P<0.05). The incomplete envelope, tumor diameter ≥5 cm, and combined cirrhosis were the main causes of recurrence of HCC (P<0.05).
conclusionProphylactic TACE significantly reduced the postoperative recurrence rate and improved the survival rate of patients with HCC. The optimal treatment efficacy was associated with interventional therapy within 1-2 months after surgery, while incomplete envelope, tumor diameter ≥5 cm, and combined cirrhosis were the high-risk factors for HCC recurrence.
Indexed as
Identifiers
35702096PMC9185034W4285741365What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.